Who are the persons living with HIV who might refuse to participate in HIV cure-related clinical trials with treatment interruption?
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
15
4
2020
medline:
9
3
2021
entrez:
15
4
2020
Statut:
ppublish
Résumé
: Achieving a HIV cure has become a research priority. As any improvement of knowledge, which could help scientists design new HIV cure-related clinical trials (HCRCT) depends on the risks potential participants are willing to accept, it is important to understand who will agree or refuse to participate and in which proportions. By providing insights into factors associated with reluctance toward HCRCT participation, our results may help clinicians in patient recruitment.
Identifiants
pubmed: 32287066
doi: 10.1097/QAD.0000000000002530
pii: 00002030-202006010-00016
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1095-1099Références
Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV 2019; 6:e259–e268.
Palich R, Ghosn J, Chaillon A, Boilet V, Nere M-L, Chaix M-L, et al. VRI02/ANRS149 LIGHT Vaccine Trial GroupViral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial. AIDS 2019; 33:279–284.
Ghosn J, Palich R, Chaillon A, Boilet V, Nere M, Delobel P, et al. VRI02/ANRS149 LIGHT Vaccine Trial GroupViral rebound in semen after treatment interruption in a HIV therapeutic vaccine double-blind trial (VRI02/ANRS149-LIGHT). J Int AIDS Soc 2017; 20:279–284.
Lévy Y, Leliévre J-D, Perrier A, Boilet V, Bouchaud O, Girard P-M, et al. Preliminary Safety Results from the VRI02 ANRS 149 Light (Lipopeptide and DNA GTU HIV Therapeutic Trial). AIDS Res Hum Retroviruses 2016; 32:406.
Ghosn J, Delaugerre C. Can we avoid treatment interruption studies in the search for an HIV cure. AIDS 2015; 29:1575–1577.
Tucker JD, Rennie S. The Social and Ethical Working Group on HIV CureSocial and ethical implications of HIV cure research. AIDS 2014; 28:1247–1250.
Chun T-W, Eisinger RW, Fauci AS. Durable control of HIV infection in the absence of antiretroviral therapy: opportunities and obstacles. JAMA 2019; 322:27–28.
Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med 2018; 24:1701–1707.
Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nat Commun 2019; 10:814.
Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, et al. Cancer Immunotherapy Trials Network (CITN)-12 Study TeamAssessment of the safety of pembrolizumab in patients with HIV and advanced cancer – a phase 1 study. JAMA Oncol 2019; 5:1332–1339.
Halper-Stromberg A, Lu C-L, Klein F, Horwitz JA, Bournazos S, Nogueira L, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014; 158:989–999.
Xu L, Wang J, Liu Y, Xie L, Su B, Mou D, et al. CRISPR-edited stem cells in a patient with hiv and acute lymphocytic leukemia. N Engl J Med 2019; 381:1240–1247.
Barré-Sinoussi F, Ross AL, Delfraissy J-F. Past, present and future: 30 years of HIV research. Nat Rev Microbiol 2013; 11:877–883.
Arnold MP, Evans D, Vergel N. Recruitment and ethical considerations in HIV cure trials requiring treatment interruption. J Virus Erad 2015; 1:43–48.
Chu CE, Wu F, He X, Ma Q, Cheng Y, Cai W, et al. Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS Res Hum Retroviruses 2015; 31:78–84.
Kuritzkes DR. Why cure, why now?. J Med Ethics 2017; 43:67–70.
Protière C, Préau M, Doumergue M, Mora M, Lambotte O, Spire B, et al. Will CURE trials introduce an uncomfortable revolution in the field of HIV research?. HIV Clin Trials 2017; 18:1–2.
Protière C, Préau M, Carrieri P, Lambotte O, Spire B, Suzan-Monti M. Importance of the patient-physician interaction in assessing acceptability of HIV cure trials. HIV Med 2017; 19:e56–e57.
Dube K, Evans D, Dee L, Sylla L, Taylor J, Skinner A, et al. ‘We Need to Deploy Them Very Thoughtfully and Carefully’: perceptions of analytical treatment interruptions in hiv cure research in the united states–a qualitative inquiry. AIDS Res Hum Retroviruses 2017; 34:67–79.
Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment . J Med Ethics. [cited 2017 Nov 28]. Available at: http://jme.bmj.com/content/early/2017/11/10/medethics-2017-104433.long.
Simmons R, Kall M, Collins S, Cairns G, Taylor S, Nelson M, et al. A global survey of HIV-positive people's attitudes towards cure research. HIV Med 2017; 18:73–79.
Kumar R. Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit ratio. J Med Ethics 2017; 43:124–127.
Buchak L. Why high-risk, nonexpected-utility-maximising gambles can be rational and beneficial: the case of HIV cure studies. J Med Ethics 2017; 43:90–95.
Jones RB. Current challenges and recent advances in the search for a cure for HIV. J Int AIDS Soc 2019; 22:e25248.
Protiere C, Arnold MP, Fiorentino M, Fressard L, Lelievre J-D, Mimi M, et al. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS-APSEC study. A discrete choice experiment. J Int AIDS Soc 2020; 23:e25443.
Protière C, Spire B, Mora M, Poizot-Martin I, Préau M, Doumergue M, et al. Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC). PLoS One 2017; 12:e0187489.
Dubé K, Evans D, Sylla L, Taylor J, Weiner BJ, Skinner A, et al. Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US. J Virus Erad 2017; 3:40–50.
Preau M, Doumergue M, Protiere C, Goujard C, Mora M, Meyer L, et al. Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC). AIDS Care 2018; 30:914–920.
Fiorentino M, Protière C, Sagaon-Teyssier L, Mimi M, Fressard L, Arnold MP, et al. What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study. J Virus Erad 2019; 5:152–162.
Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature. Vaccine 2014; 32:2150–2159.
Peretti-Watel P, Larson HJ, Ward JK, Schulz WS, Verger P. Vaccine Hesitancy: Clarifying a Theoretical Framework for an Ambiguous Notion. PLoS Curr 2015; pii: ecurrents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289.
pii: ecurrents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289
Kumar D, Chandra R, Mathur M, Samdariya S, Kapoor N. Vaccine hesitancy: understanding better to address better. Isr J Health Policy Res 2016; 5:2.
Detoc M, Launay O, Dualé C, Mutter C, Le Huec J-C, Lenzi N, et al. Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites. Vaccine 2019; 37:6633–6639.
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. Hum Vaccines Immunother 2013; 9:1763–1773.
Rey D, Fressard L, Cortaredona S, Bocquier A, Gautier A, Peretti-Watel P, et al. Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk-benefit balance. Euro Surveill 2018; 23: 17-00816.
Broadbent JJ. Vaccine hesitancy: misinformation on social media. BMJ 2019; 66:l4457.
Verger P, Bocquier A, Vergélys C, Ward J, Peretti-Watel P. Flu vaccination among patients with diabetes: motives, perceptions, trust, and risk culture - a qualitative survey. BMC Public Health 2018; 18:569.
Protière C, Donaldson C, Moatti JP, Luchini S, Shackley P. The impact of information on nonhealth attributes on willingness to pay for multiple healthcare programmes. Soc Sci Med 2004; 58:1257–1269.
van de Mortel T. Faking it: social desirability response bias in self-report research. Aust J Adv Nurs 2008; 25:40–48.
Edwards AL. The relationship between the judged desirability of a trait and the probability that the trait will be endorsed. J. Appl Psychol 1953; 37:90–93.
Ma Q, Wu F, Henderson G, Rennie S, Rich ZC, Cheng Y, et al. ‘I can coexist with HIV’: a qualitative study of perceptions of HIV cure among people living with HIV in Guangzhou, China. J Virus Erad 2016; 2:170–174.
Moodley K, Staunton C, de Roubaix M, Cotton M. HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives. Aids Care-Psychol Socio-Med Asp AidsHiv 2016; 28:524–527.